Showing results (111-120 of 137) with videos related to

Sort By:
Pageof 14
Scientific Reports|July 5, 2026
Early systemic inflammatory-metabolic trajectory phenotypes are associated with survival outcomes in metastatic renal cell carcinoma treated with nivolumabOndřej Fiala, Tomas Buchler, Alexandr Poprach, et al.
Frontiers in Immunology|July 15, 2026
Nivolumab in previously treated metastatic renal cell carcinoma: real-world data from the Czech Republic and SlovakiaOndřej Fiala, Michaela Tkadlecová, Tomas Buchler, et al.
Clinical Genitourinary Cancer|December 13, 2023
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 StudyFernando Sabino Marques Monteiro, Ondřej Fiala, Francesco Massari, et al.
Scientific Reports|December 21, 2025
Baseline and early changes in eosinophil count and neutrophil-to-eosinophil ratio predict outcomes in metastatic renal cell carcinoma treated with nivolumabOndřej Fiala, Katarína Rejleková, Tomas Buchler, et al.
British Journal of Cancer|June 2, 2026
Risk factors and causes of early death in germ cell tumors: a Global Society for Rare GU tumors studyMichal Mego, Edgar Israelyan, Robert J Hamilton, et al.
International Journal of Cancer|December 31, 2024
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trialViktor Grünwald, Rana R McKay, Tomas Buchler, et al.
Targeted Oncology|August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination TherapiesMatteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
Frontiers in Oncology|March 18, 2024
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib armsViktor Grünwald, Thomas Powles, Masatoshi Eto, et al.
Frontiers in Oncology|September 4, 2023
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib armsViktor Grünwald, Thomas Powles, Masatoshi Eto, et al.
European Urology Oncology|June 4, 2026
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 StudyPhilipp Cornelius Mandel, Mike Wenzel, María Natalia Gandur Quiroga, et al.
Pageof 14